Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years.

James Foran, MD, Angelina The, MD, Pam Dixon, RN, Marcel Devetten, MD, Mikkael Sekeres, MD

Blood (2007) 110 (11): 1831.

https://doi.org/10.1182/blood.V110.11.1831.1831

Published: 2007

Journal Articles

Effect of T Cell Recovery on Overall Survival (OS) Following Pentostatin Conditioning for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).

James E. Talmadge, PhD, Ugur Coskun, PhD, Sarah Maas, MS, Orhan Turken, MD, Ziviko S. Pavletic, MD, Charles A. Kuszynski, PhD, Marcel Devetten, MD, Laura R. Schafer, MS, Lori Zobel, BS, Robert G. Bociek, MD

Blood (2007) 110 (11): 2994.

https://doi.org/10.1182/blood.V110.11.2994.2994

Published: 2007

Journal Articles

A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.

Kenneth B. Miller, MD, Nelson J. Chao, MD, Hans A. Messner, MD,PhD, Steven C. Goldstein, MD, Vijay Reddy, MD,PhD, William Vaughan, MD, Steven Devine, MD, Scott D. Rowley, MD, Ned Waller, MD,PhD, Marcel Devetten, MD, Gary J. Schiller, MD

Blood (2006) 108 (11): 5369.

https://doi.org/10.1182/blood.V108.11.5369.5369

Published: 2006

Journal Articles

Differential T Cell Suppression by Two Different Pentostatin Conditioning Protocols for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).

Ugur Coskun, MD, Robert G. Bociek, MD, Zivko S. Pavletic, MD, Charlie Kuszynski, PhD, Marcel Devetten, MD, Laura Shafer, Lori Zobel, James E. Talmadge, PhD

Blood (2006) 108 (11): 5373.

https://doi.org/10.1182/blood.V108.11.5373.5373

Published: 2006

Journal Articles

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

Partow Kebriaei, MD, Luis Isola, MD, Erkut Bahceci, MD, H. Kent Holland, MD, Scott Rowley, MD, Joseph McGuirk, DO, Marcel Devetten, MD, Jan Jansen, MD, PhD, Roger Herzig, MD, Michael Schuster, MD, Joseph Uberti, MD, PhD

Blood (2006) 108 (11): 3231.

https://doi.org/10.1182/blood.V108.11.3231.3231

Published: 2006

Journal Articles

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Mark Levis, MD, PhD, B. Douglas Smith, MD, Miloslav Beran, MD, Maria R. Baer, MD, Harry P. Erba, MD, Larry Cripe, MD, Steven Coutre, MD, Anjali Advani, MD, Alexander Perl, MD, Marcel Devetten, MD, Robert Stuart, MD, Martin S. Tallman, MD, Peter Brown, PhD, Lothar Tremmel, Donald Small, MD, PhD

Blood (2005) 106 (11): 403.

https://doi.org/10.1182/blood.V106.11.403.403

Published: 2005

Journal Articles

Phase I/II Study of Clofarabine Combined with Standard Dose Cytarabine as Remission Induction Therapy of De Novo AML in Elderly Patients ≥60 Years.

James M. Foran, MD, Angeline S. The, MD, Marcel Devetten, MD, Sreelatha Meleth, PhD, Jeff Worrell, BSN, Pam Dixon, BSN, Mikkael A. Sekeres, MD, MS

Blood (2005) 106 (11): 4635.

https://doi.org/10.1182/blood.V106.11.4635.4635

Published: 2005

NARROW

Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years.

Effect of T Cell Recovery on Overall Survival (OS) Following Pentostatin Conditioning for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).

A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.

Differential T Cell Suppression by Two Different Pentostatin Conditioning Protocols for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Phase I/II Study of Clofarabine Combined with Standard Dose Cytarabine as Remission Induction Therapy of De Novo AML in Elderly Patients ≥60 Years.

Email alerts

ASH Publications

American Society of Hematology

Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years.

Effect of T Cell Recovery on Overall Survival (OS) Following Pentostatin Conditioning for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).

A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.

Differential T Cell Suppression by Two Different Pentostatin Conditioning Protocols for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Phase I/II Study of Clofarabine Combined with Standard Dose Cytarabine as Remission Induction Therapy of De Novo AML in Elderly Patients ≥60 Years.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only